Abstract: Objective To investigate the expression of long non-coding RNA MEG3（lncRNA MEG3） in small cell lung cancer（SCLC）and its correlation with prognosis. Methods Ninety-two cases of SCLC tissue from January 2012 to December 2015 were enrolled in this study. The expression of lncRNA MEG3 of SCLC tissues， adjacent normal tissues and normal lung tissues were detected by QPCR. The correlation of lncRNA MEG3 with clinicopathological characteristics as well as prognosis was analyzed. Results Compared with adjacent normal tissue（4.082±0.86）and normal lung tissues（4.209±0.82）， the expression of lncRNA MEG3 in 92 cases of tumor tissue （2.071±0.97） was significantly decreased. The expression of lncRNA MEG3 was related with stage， distant metastasis and survival status （P＜0.05）， but not with gender and ages （P＞0.05）. Kaplan-Meier analysis demonstrated that the median progression-free survival and overall survival of patients with low expression of lncRNA MEG3 was 8 months and 21 months， lower than 21 months and 32 months of patients with high expression of lncRNA MEG3 （P＜0.001）. Multivariate Cox regression analysis indicated that MEG3 expression， stage and distant metastasis were independent factors influencing OS. Conclusion LncRNA MEG3 is involved in the development of SCLC， and can be used as a molecular biomarker for prognostic prediction of the evaluate SCLC.